MX2009012420A - Reovirus mutantes y metodos para elaboracion y uso. - Google Patents

Reovirus mutantes y metodos para elaboracion y uso.

Info

Publication number
MX2009012420A
MX2009012420A MX2009012420A MX2009012420A MX2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A
Authority
MX
Mexico
Prior art keywords
methods
mutant reovirus
mutant
making
isvp
Prior art date
Application number
MX2009012420A
Other languages
English (en)
Spanish (es)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX2009012420A publication Critical patent/MX2009012420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009012420A 2007-05-21 2008-05-21 Reovirus mutantes y metodos para elaboracion y uso. MX2009012420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93925507P 2007-05-21 2007-05-21
PCT/CA2008/000964 WO2008141448A1 (en) 2007-05-21 2008-05-21 Mutant reoviruses and methods of making and using

Publications (1)

Publication Number Publication Date
MX2009012420A true MX2009012420A (es) 2009-12-09

Family

ID=40031362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012420A MX2009012420A (es) 2007-05-21 2008-05-21 Reovirus mutantes y metodos para elaboracion y uso.

Country Status (14)

Country Link
US (1) US20080292594A1 (enExample)
EP (1) EP2150613B1 (enExample)
JP (1) JP2010527593A (enExample)
CN (2) CN104195115A (enExample)
AR (1) AR066649A1 (enExample)
AU (1) AU2008253505B2 (enExample)
CA (1) CA2680661C (enExample)
DK (1) DK2150613T3 (enExample)
ES (1) ES2611455T3 (enExample)
IL (1) IL200690A (enExample)
MX (1) MX2009012420A (enExample)
TW (1) TW200909581A (enExample)
WO (1) WO2008141448A1 (enExample)
ZA (1) ZA200907017B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
EP2211880A4 (en) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물
EP4268837A4 (en) * 2020-12-22 2025-05-07 Virocure, Inc. NEW MODIFIED REOVIRUS AND ITS USE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
ES2301241T3 (es) * 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2189162T3 (da) * 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK2253701T3 (da) * 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders

Also Published As

Publication number Publication date
EP2150613B1 (en) 2016-10-19
US20080292594A1 (en) 2008-11-27
TW200909581A (en) 2009-03-01
CN104195115A (zh) 2014-12-10
AU2008253505A1 (en) 2008-11-27
AU2008253505B2 (en) 2014-09-04
AR066649A1 (es) 2009-09-02
IL200690A (en) 2014-02-27
HK1136006A1 (en) 2010-06-18
CA2680661C (en) 2018-05-29
ZA200907017B (en) 2010-12-29
CA2680661A1 (en) 2008-11-27
EP2150613A4 (en) 2011-01-19
ES2611455T3 (es) 2017-05-09
JP2010527593A (ja) 2010-08-19
DK2150613T3 (en) 2017-01-30
IL200690A0 (en) 2011-08-01
EP2150613A1 (en) 2010-02-10
WO2008141448A1 (en) 2008-11-27
CN101679953A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
MX2009009598A (es) Reovirus que tienen secuencias modificadas.
MX339584B (es) Inhibidores de pi3 cinasa y usos de los mismos.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2009013170A (es) Particulas de silice y metodos para prepararlas y utilizarlas.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MX2010004374A (es) Armazones proteinicos.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
PH12023500023A1 (en) Cdk2 degraders and uses thereof
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
MY161495A (en) Virus like particle compositions and methods of use
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
TN2011000655A1 (en) Mesenchymal stem cell differentiation
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
IN2015MN00027A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration